🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today Elisabeth Sonesson, VP, Global Franchise Lead Autoimmunity, at Hansa Biopharma is speaking at SEB Annual Healthcare Seminar in Stockholm sharing how we advance innovative science to address IgG-driven autoimmune diseases with high unmet medical need. hansabiopharma.com/investors/pres…

For investors and media Today GENETHON France and Hansa Biopharma announced the initiation of a Phase 2 trial of their #genetherapy in patients with severe Crigler-Najjar Syndrome who have anti-AVV antibodies and have received Hansa’s IgG cleaving treatment. hansabiopharma.com/media/press-re…

For investors and media: Today Hansa Biopharma announced the completion of enrolment in GOOD-IDES-02, a global pivotal Phase 3 trial in anti-GBM. Read more here: hansabiopharma.com/media/press-re…

We applaud the EU Council's call for the EU Commission to update the EU Action Plan on #organdonation and #transplantation. Addressing inequities and reducing waiting times for highly sensitized patients is crucial.

For investors and media: Today Hansa Biopharma announced positive full results from the 15-HMedIdeS-09 phase 2 study in GBS including an indirect treatment comparison to data from the IGOS database. Telephone conference: Dec 18 14:00 CET / 8:00 AM EST. hansabiopharma.com/media/press-re…

Earlier this month results of an extended pooled analysis using data from Hansa Biopharma's 17-HMedIdeS-14 study were published in the American Journal of Transplantation amjtransplant.org/article/S1600-…

Next week, Hansa Biopharma will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. We’re excited to share the progress we’ve made in 2024 as well as upcoming pipeline catalysts in 2025. hansabiopharma.com/media/press-re…

Collaboration is fundamental for the successful development of innovative treatments. This is especially important in rare diseases, where currently less than 10% have an approved treatment option and there remains an urgent need. hansabiopharma.com/media/media-ar…

For investors and media: today Hansa Biopharma published its year-end financial report for 2024, closing a year marked by key progress in the development pipeline and strong sales performance. hansabiopharma.com/media/press-re…

People living with rare diseases face unique challenges that impact their quality of life and role in society. As scientific and medical advancement continues, there remains an urgent need to provide treatments to rare disease patients #RareDiseaseDay rarediseaseday.org

During this year’s #RareDiseaseDay Hansa Biopharma maintains its commitment to advancing innovative science, delivering new treatments and helping to ensure equitable access to care for people living with rare diseases.

For investors and media: Today Hansa Biopharma announced completion of enrolment in the European Post Authorization Efficacy and Safety (PAES) study. hansabiopharma.com/media/press-re…

We are thrilled to be attending the BTS and NHS Blood+Transplant Joint Congress 2025 and hear from the medical and scientific communities about the latest advancements in transplantation care in the UK.

Today is #WorldKidneyDay and Hansa Biopharma joins the kidney community in elevating the need for patients to have access to care across the entire spectrum of kidney disease, from prevention to treatment, including transplantation. Visit worldkidneyday.org to know more.

Today, Hansa Biopharma publishes its Annual Report and Sustainability Report for 2024, a year marked by strong sales growth and key advancements in clinical development in the Company’s three focus areas of Autoimmune, Gene therapy, and Transplantation.

There is a need for better treatment options for rare diseases to improve the quality of patients’ lives and reduce healthcare systems costs. We are committed to advance the science of innovative new treatments to address the unmet need in rare disease. hansabiopharma.com/media/media-ar…

Antibodies, including IgG, are an important part of the immune system. In some situations, including in autoimmune conditions, these antibodies and the antibody-driven immune response, can be harmful and lead to lasting damage to the organs and other parts of the body.

Join Hansa Biopharma $HNSA for a virtual investor event on June 16 at 14 CEST/8 AM ET with company leadership and KOLs David R. Cornblath, MD and Simon Rinaldi, MRCP, PhD, who will discuss the unmet need and current treatment landscape for GBS. Register: event.choruscall.com/mediaframe/web…

For investors and media: Today Hansa Biopharma published its Interim Financial Report for the first quarter of 2025 delivering solid product sales and pipeline progress. Hansa will host a conference call today, 24 April, at 14:00 CEST / 8:00 am ET. hansabiopharma.com/media/press-re…

Hansa Biopharma is excited to welcome Renée Aguiar-Lucander as the Company’s Chief Executive Officer.